Serum levels of sIL-2, together with its receptor IL-2Rα, were significantly higher in patients with myeloproliferative diseases than in healthy controls [37] and were increased by ruxolitinib but decreased by pacritinib. Here, IL2RA is linked to myeloproliferative disorder.